Background: The use of rtCGM remains largely investigational in the hospital setting. The current study aimed to evaluate the effect of rtCGM in inpatients with diabetes treated with short-term continuous subcutaneous insulin infusion (CSII).
Methods: In endocrinology wards located in a tertiary hospital, we assigned 475 adults with type 1 and type 2 diabetes requiring short-term CSII during hospitalization, to receive either rtCGM program (Figure 1) (n=237) or point-of-care (POC) standard of care with blinded CGM (n=238). Primary outcome was the difference in the percentage of time within the target glucose range of 3.9 to 10 mmol/L (TIR, %).
Results: The mean TIR was 71.1±15.8 % in the rtCGM group and 62.9±18.9 % in the POC group (P<0.001). The mean time above range >10mmol/L was significantly lower in rtCGM group than in POC group (28.3±15.8% vs. 36.6±19.0%, P<0.001), whereas there was no significant between-group difference in the time below range <3.9mmol/L (P=0.11). Moreover, the time to reach target glucose was significantly shorter in rtCGM group than in POC group (2.0 [1.0-4.0] vs. 4.0 [2.0-5.0] days, P<0.001).
Conclusion: In inpatients with diabetes receiving short-term CSII, rtCGM program resulted in better glucose control than POC standard of care, without increasing the risk of hypoglycemia.
Y. Wang: None. J. Lu: None. M. Wang: None. J. Ni: None. W. Lu: None. W. Zhu: None. Y. Bao: None. J. Zhou: None.
